Abeona Therapeutics Inc (NASDAQ:ABEO) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the stock. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $17.20.
Several equities analysts have commented on ABEO shares. Zacks Investment Research lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 14th. Jefferies Group LLC reissued a “buy” rating and issued a $11.00 target price on shares of Abeona Therapeutics in a report on Friday, February 17th. Maxim Group set a $14.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Friday, February 17th. Cantor Fitzgerald set a $21.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Monday, December 12th. Finally, HC Wainwright set a $20.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Monday, February 6th.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 4.80 on Monday. Abeona Therapeutics has a 1-year low of $2.27 and a 1-year high of $9.44. The company’s 50 day moving average is $5.20 and its 200-day moving average is $5.71. The company’s market capitalization is $191.80 million.
Large investors have recently bought and sold shares of the stock. A.R.T. Advisors LLC bought a new stake in Abeona Therapeutics during the fourth quarter worth $117,000. RTW Investments LLC bought a new stake in Abeona Therapeutics during the third quarter worth $116,000. Ardsley Advisory Partners bought a new stake in Abeona Therapeutics during the third quarter worth $120,000. Highbridge Capital Management LLC bought a new stake in Abeona Therapeutics during the third quarter worth $1,591,000. Finally, GLG Partners LP bought a new stake in Abeona Therapeutics during the fourth quarter worth $186,000. Institutional investors own 17.79% of the company’s stock.
WARNING: This piece of content was originally published by Web Breaking News and is the sole property of of Web Breaking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at http://www.webbreakingnews.com/2017/03/25/abeona-therapeutics-inc-abeo-receives-average-recommendation-of-buy-from-analysts.html.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.